Q1 FY27 results: Revenue up 31% YoY, PAT down 31% YoY

Revenue growth above 20%Net loss reportedEBITDA margin compressionResults View source PDF Explain this filing

SUPRIYA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.8%Reaction day

₹813.50

prior close

₹745.00

announcement price

After-mkt

timing

Nifty Microcap 250market+0.1%-2.8% vs market

Pharmaceuticals peers, median of 166sector-0.4%-2.4% vs sector

On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+4.0

10m

+5.1

15m

+3.4

30m

+5.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.8+0.1-2.8-0.4-2.4

Next day

-4.0+0.2-4.2-0.3-3.7

-1.2+0.6-1.8-0.5-0.7

-3.1-0.0-3.1-1.3-1.8

-0.2+0.5-0.7-0.9+0.7

-0.9+0.8-1.7-0.4-0.5

-2.8+0.6-3.3-0.9-1.9

15d

+4.0+1.3+2.7+0.0+4.0

+7.4-1.4+8.8-0.1+7.6

+6.9-0.6+7.5-2.8+9.7

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Supriya Lifescience posted Q1 FY27 revenue of Rs 1,897.47 mn, up 30.8% YoY from Rs 1,450.74 mn. However, PAT fell 30.9% YoY to Rs 240.43 mn from Rs 347.90 mn on sharp cost pressure. Cost of materials consumed surged to Rs 1,094 mn from Rs 437.76 mn and other expenses rose to Rs 574 mn from Rs 389 mn. EPS stood at Rs 2.99 vs Rs 4.32. Auditor Kakaria and Associates issued an unqualified limited review report. Company disclosed material detained by Customs at quarter end, already booked as sale.

Likely market impact

Mixed results: strong top-line growth but sharp PAT fall as costs surged; overall profit margins compressed sharply versus last year.